Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| C06CA059267 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to characterize the effects of high energy radiation on bone breakdown, with a specific interest in reducing the rate of sacral fractures. Although radiation is very important in managing tumors, it is related to complications such as bone fractures. In this research study, the investigators are looking to determine changes in blood markers, bone density, and bone structure following radiation and to better understand the reason for these changes.
Participants in the Surgical Arm of the study will be treated according to the schedule outlined in protocol for a combined treatment with surgery and adjuvant high dose radiotherapy. Patients in the non surgical arm of the the study will be treated according to the protocol being treated with radiotherapy alone.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non Surgical-Radiation Only | Experimental | Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma |
|
| Malignant Tumor Surgery And Radiation | Experimental | The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radiation (Surgical Arm) | Radiation | For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Bone Mineral Density (Tb. BMD) | Trabecular bone mineral density will be measured in mg/cm3 using volumetric Quantitative Computed Tomography (QCT) of L1, L2 and the vertebrae adjacent to the tumor. | Non-surgical arm: baseline, 3 months Surgical arm: baseline, 9 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Serum N-Telopeptide (NTX) | Indicator for Bone Formation, units reported in nmol NTX/mmol creatinine | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
| Serum Tartrate-resistant Acid Phosphatase 5b (TRAP5b) |
Not provided
Inclusion Criteria:
All laboratory tests that are a part of the eligibility criteria must be completed within 14 days prior to the date of registration. Diagnostic tests that are a part of the eligibility criteria must be performed within 30 days of the date of registration. Participants must meet the following criteria on screening examination to be eligible to participate in the study:
Study participants must have histologically confirmed primary malignant bone tumor in the sacrum for which surgery and radiation or radiation alone are planned.
Age 18 years or older. In children under the age of 8, tetracycline derivatives have been reported to stain tooth enamel yellow color. These considerations lead us to exclude young persons under the age of 18 from the study.
Participants must have normal organ and marrow function as defined below:
The effects of tetracyclines and radiation used in computer tomography on the developing human fetus are known to be detrimental. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Participants must be able to read and understand English language and have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joseph H. Schwab, MD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Non Surgical-Radiation Only | Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) |
| FG001 | Malignant Tumor Surgery And Radiation | The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later. Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) Malignant Tumor Surgery: Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Non Surgical-Radiation Only | Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Bone Mineral Density (Tb. BMD) | Trabecular bone mineral density will be measured in mg/cm3 using volumetric Quantitative Computed Tomography (QCT) of L1, L2 and the vertebrae adjacent to the tumor. | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. | Posted | Number | mg/cm^3 | Non-surgical arm: baseline, 3 months Surgical arm: baseline, 9 weeks |
|
From first dose of study treatment to final study date per patient, approximately 10 months.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Non Surgical-Radiation Only | Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Allergic reaction | General disorders | Non-systematic Assessment | Patient had an allergic reaction to then non-investigational FDA approved bone labeling drugs (demeclocycline). |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Joseph Schwab | Massachusetts General Hospital | 617-643-0547 | JHSCHWAB@PARTNERS.ORG |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 5, 2016 | Jun 9, 2021 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Apr 10, 2017 | Nov 8, 2021 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D011827 | Radiation |
| ID | Term |
|---|---|
| D055585 | Physical Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Radiation (Non-surgical Arm) | Radiation | Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) |
|
| Malignant Tumor Surgery | Procedure | Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor |
|
Indicator for Bone Formation, units reported in U/L |
| Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
| Serum Osteocalcin (OC) | Indicator for Bone Formation, units reported in ng/mL | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
| Serum Type 1 Procollagen N-terminal (P1NP) | Indicator for systemic metabolism that can affect bone health, units reported in pg/mL | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
| Serum Phosphate (P) | Indicators for systemic metabolism that can affect bone health, units reported in mg/dL | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
| Serum 25-hydroxycalciferol Vit D (25-OH VitD) | Indicators for systemic metabolism that can affect bone health, units reported in nmol/L | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
| Mineral Apposition Rate (MAR) | Tetracycline quadruple labeling method will be used and the unit of measure will be um/day | Only surgical arm: The months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear. |
| Bone Formation Rate (BFR/BS) | Tetracycline quadruple labeling method will be used and the unit of measure will be mm3/mm2/year | Only surgical arm: The months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear. |
| Mineralization Lag Time (Mlt) | Tetracycline quadruple labeling method will be used and the unit of measure will be days | Only surgical arm: The months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear. |
| Osteoblast Number (N.Ob/BPm) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
| Osteoblast Surface (Ob. S/BS) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
| Osteoclast Number (N.Oc/BPm) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
| Osteoclast Surface (Oc.S/BS) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
| Patient did not have surgery as planned. |
|
| BG001 | Malignant Tumor Surgery And Radiation | The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later. Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) Malignant Tumor Surgery: Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| OG001 | Malignant Tumor Surgery And Radiation | The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later. Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) Malignant Tumor Surgery: Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor |
|
|
| Secondary | Serum N-Telopeptide (NTX) | Indicator for Bone Formation, units reported in nmol NTX/mmol creatinine | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | nM/L | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
|
|
|
| Secondary | Serum Tartrate-resistant Acid Phosphatase 5b (TRAP5b) | Indicator for Bone Formation, units reported in U/L | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | U/L | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
|
|
|
| Secondary | Serum Osteocalcin (OC) | Indicator for Bone Formation, units reported in ng/mL | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | ng/mL | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
|
|
|
| Secondary | Serum Type 1 Procollagen N-terminal (P1NP) | Indicator for systemic metabolism that can affect bone health, units reported in pg/mL | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | pg/mL | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
|
|
|
| Secondary | Serum Phosphate (P) | Indicators for systemic metabolism that can affect bone health, units reported in mg/dL | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | mg/dL | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
|
|
|
| Secondary | Serum 25-hydroxycalciferol Vit D (25-OH VitD) | Indicators for systemic metabolism that can affect bone health, units reported in nmol/L | Subjects 4 and 9 are in the non-surgical radiation group and only have values for that column. The rest of the subjects are in the malignant tumor surgery and radiation and only have values in that column. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | nmol/L | Non-surgical arm: baseline, 3.5 weeks, 7 weeks, ~5 months, ~8 months Surgical arm: baseline, 5.5 weeks, 18.5 weeks, ~7 months, ~10 months |
|
|
|
| Secondary | Mineral Apposition Rate (MAR) | Tetracycline quadruple labeling method will be used and the unit of measure will be um/day | B = before radiation, A = after radiation. For missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | um/day | Only surgical arm: The months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear. |
|
|
|
| Secondary | Bone Formation Rate (BFR/BS) | Tetracycline quadruple labeling method will be used and the unit of measure will be mm3/mm2/year | B = before radiation, A = after radiation. For missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | mm3/mm2/year | Only surgical arm: The months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear. |
|
|
|
| Secondary | Mineralization Lag Time (Mlt) | Tetracycline quadruple labeling method will be used and the unit of measure will be days | A = after radiation. No periosteal data for any subject. For other missing values, certain tests were not performed at certain timepoints for some subjects. | Posted | Number | days | Only surgical arm: The months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear. |
|
|
|
| Secondary | Osteoblast Number (N.Ob/BPm) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | No biopsy data for subjects 10 and 12. | Posted | Number | 1/mm | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
|
|
|
| Secondary | Osteoblast Surface (Ob. S/BS) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | No biopsy data for subjects 10 and 12. | Posted | Number | 1/mm | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
|
|
|
| Secondary | Osteoclast Number (N.Oc/BPm) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | No biopsy data for subjects 10 and 12. | Posted | Number | 1/mm | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
|
|
|
| Secondary | Osteoclast Surface (Oc.S/BS) | Immunohistochemistry staining methods will be used and the unit of measure will be mm^-1 | No biopsy data for subjects 10 and 12. | Posted | Number | 1/mm | Only surgical arm: The weeks after biopsies are taken during surgery (surgery is during week 4 and 5). |
|
|
|
| 0 |
| 2 |
| 0 |
| 2 |
| 0 |
| 2 |
| EG001 | Malignant Tumor Surgery And Radiation | The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later. Radiation: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma) Malignant Tumor Surgery: Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor | 0 | 10 | 1 | 10 | 0 | 10 |
|
Not provided
Not provided
| Subject 2 (5.5 weeks) |
|
|
| Subject 2 (18.5 Weeks) |
|
|
| Subject 2 (about 7 months) |
|
|
| Subject 2 (about 10 months) |
|
|
| Subject 3 (baseline) |
|
|
| Subject 3 (5.5 weeks) |
|
|
| Subject 3 (18.5 weeks) |
|
| Subject 3 (about 7 months) |
|
| Subject 3 (about 10 months) |
|
| Subject 4 (baseline) |
|
|
| Subject 4 (3.5 weeks) |
|
|
| Subject 4 (7 weeks) |
|
|
| Subject 4 (about 5 months) |
|
| Subject 4 (about 8 months) |
|
|
| Subject 6 (baseline) |
|
|
| Subject 6 (5.5 weeks) |
|
|
| Subject 6 (18.5 weeks) |
|
|
| Subject 6 (about 7 months) |
|
|
| Subject 6 (about 10 months) |
|
|
| Subject 7 (baseline) |
|
|
| Subject 7 (5.5 weeks) |
|
|
| Subject 7 (18.5 weeks) |
|
|
| Subject 7 (about 7 months) |
|
| Subject 7 (about 10 months) |
|
|
| Subject 8 (baseline) |
|
|
| Subject 8 (5.5 weeks) |
|
|
| Subject 8 (18.5 weeks) |
|
|
| Subject 8 (about 7 months) |
|
|
| Subject 8 (about 10 months) |
|
|
| Subject 9 (baseline) |
|
|
| Subject 9 (3.5 weeks) |
|
|
| Subject 9 (7 weeks) |
|
|
| Subject 9 (about 5 months) |
|
|
| Subject 9 (about 8 months) |
|
|
| Subject 10 (baseline) |
|
|
| Subject 10 (5.5 weeks) |
|
|
| Subject 10 (18.5 weeks) |
|
|
| Subject 10 (about 7 months) |
|
|
| Subject 10 (about 10 months) |
|
| Subject 12 (baseline) |
|
|
| Subject 12 (5.5 weeks) |
|
|
| Subject 12 (18.5 weeks) |
|
|
| Subject 12 (about 7 months) |
|
|
| Subject 12 (about 10 months) |
|
| Subject 2 (5.5 weeks) |
|
|
| Subject 2 (18.5 Weeks) |
|
|
| Subject 2 (about 7 months) |
|
|
| Subject 2 (about 10 months) |
|
|
| Subject 3 (baseline) |
|
|
| Subject 3 (5.5 weeks) |
|
|
| Subject 3 (18.5 weeks) |
|
| Subject 3 (about 7 months) |
|
| Subject 3 (about 10 months) |
|
| Subject 4 (baseline) |
|
|
| Subject 4 (3.5 weeks) |
|
|
| Subject 4 (7 weeks) |
|
|
| Subject 4 (about 5 months) |
|
| Subject 4 (about 8 months) |
|
|
| Subject 6 (baseline) |
|
|
| Subject 6 (5.5 weeks) |
|
|
| Subject 6 (18.5 weeks) |
|
|
| Subject 6 (about 7 months) |
|
|
| Subject 6 (about 10 months) |
|
|
| Subject 7 (baseline) |
|
|
| Subject 7 (5.5 weeks) |
|
|
| Subject 7 (18.5 weeks) |
|
|
| Subject 7 (about 7 months) |
|
| Subject 7 (about 10 months) |
|
|
| Subject 8 (baseline) |
|
|
| Subject 8 (5.5 weeks) |
|
|
| Subject 8 (18.5 weeks) |
|
|
| Subject 8 (about 7 months) |
|
|
| Subject 8 (about 10 months) |
|
|
| Subject 9 (baseline) |
|
|
| Subject 9 (3.5 weeks) |
|
|
| Subject 9 (7 weeks) |
|
|
| Subject 9 (about 5 months) |
|
|
| Subject 9 (about 8 months) |
|
|
| Subject 10 (baseline) |
|
|
| Subject 10 (5.5 weeks) |
|
|
| Subject 10 (18.5 weeks) |
|
|
| Subject 10 (about 7 months) |
|
|
| Subject 10 (about 10 months) |
|
| Subject 12 (baseline) |
|
|
| Subject 12 (5.5 weeks) |
|
|
| Subject 12 (18.5 weeks) |
|
|
| Subject 12 (about 7 months) |
|
|
| Subject 12 (about 10 months) |
|
| Subject 2 (5.5 weeks) |
|
|
| Subject 2 (18.5 Weeks) |
|
|
| Subject 2 (about 7 months) |
|
|
| Subject 2 (about 10 months) |
|
|
| Subject 3 (baseline) |
|
|
| Subject 3 (5.5 weeks) |
|
|
| Subject 3 (18.5 weeks) |
|
| Subject 3 (about 7 months) |
|
| Subject 3 (about 10 months) |
|
| Subject 4 (baseline) |
|
|
| Subject 4 (3.5 weeks) |
|
|
| Subject 4 (7 weeks) |
|
|
| Subject 4 (about 5 months) |
|
| Subject 4 (about 8 months) |
|
|
| Subject 6 (baseline) |
|
|
| Subject 6 (5.5 weeks) |
|
|
| Subject 6 (18.5 weeks) |
|
|
| Subject 6 (about 7 months) |
|
|
| Subject 6 (about 10 months) |
|
|
| Subject 7 (baseline) |
|
|
| Subject 7 (5.5 weeks) |
|
|
| Subject 7 (18.5 weeks) |
|
|
| Subject 7 (about 7 months) |
|
| Subject 7 (about 10 months) |
|
|
| Subject 8 (baseline) |
|
|
| Subject 8 (5.5 weeks) |
|
|
| Subject 8 (18.5 weeks) |
|
|
| Subject 8 (about 7 months) |
|
|
| Subject 8 (about 10 months) |
|
|
| Subject 9 (baseline) |
|
|
| Subject 9 (3.5 weeks) |
|
|
| Subject 9 (7 weeks) |
|
|
| Subject 9 (about 5 months) |
|
|
| Subject 9 (about 8 months) |
|
|
| Subject 10 (baseline) |
|
|
| Subject 10 (5.5 weeks) |
|
|
| Subject 10 (18.5 weeks) |
|
|
| Subject 10 (about 7 months) |
|
|
| Subject 10 (about 10 months) |
|
| Subject 12 (baseline) |
|
|
| Subject 12 (5.5 weeks) |
|
|
| Subject 12 (18.5 weeks) |
|
|
| Subject 12 (about 7 months) |
|
|
| Subject 12 (about 10 months) |
|
| Subject 2 (5.5 weeks) |
|
|
| Subject 2 (18.5 Weeks) |
|
|
| Subject 2 (about 7 months) |
|
|
| Subject 2 (about 10 months) |
|
|
| Subject 3 (baseline) |
|
|
| Subject 3 (5.5 weeks) |
|
|
| Subject 3 (18.5 weeks) |
|
| Subject 3 (about 7 months) |
|
| Subject 3 (about 10 months) |
|
| Subject 4 (baseline) |
|
|
| Subject 4 (3.5 weeks) |
|
|
| Subject 4 (7 weeks) |
|
|
| Subject 4 (about 5 months) |
|
| Subject 4 (about 8 months) |
|
|
| Subject 6 (baseline) |
|
|
| Subject 6 (5.5 weeks) |
|
|
| Subject 6 (18.5 weeks) |
|
|
| Subject 6 (about 7 months) |
|
|
| Subject 6 (about 10 months) |
|
|
| Subject 7 (baseline) |
|
|
| Subject 7 (5.5 weeks) |
|
|
| Subject 7 (18.5 weeks) |
|
|
| Subject 7 (about 7 months) |
|
| Subject 7 (about 10 months) |
|
|
| Subject 8 (baseline) |
|
|
| Subject 8 (5.5 weeks) |
|
|
| Subject 8 (18.5 weeks) |
|
|
| Subject 8 (about 7 months) |
|
|
| Subject 8 (about 10 months) |
|
|
| Subject 9 (baseline) |
|
|
| Subject 9 (3.5 weeks) |
|
|
| Subject 9 (7 weeks) |
|
|
| Subject 9 (about 5 months) |
|
|
| Subject 9 (about 8 months) |
|
|
| Subject 10 (baseline) |
|
|
| Subject 10 (5.5 weeks) |
|
|
| Subject 10 (18.5 weeks) |
|
|
| Subject 10 (about 7 months) |
|
|
| Subject 10 (about 10 months) |
|
| Subject 12 (baseline) |
|
|
| Subject 12 (5.5 weeks) |
|
|
| Subject 12 (18.5 weeks) |
|
|
| Subject 12 (about 7 months) |
|
|
| Subject 12 (about 10 months) |
|
| Subject 2 (5.5 weeks) |
|
|
| Subject 2 (18.5 Weeks) |
|
|
| Subject 2 (about 7 months) |
|
|
| Subject 2 (about 10 months) |
|
|
| Subject 3 (baseline) |
|
|
| Subject 3 (5.5 weeks) |
|
|
| Subject 3 (18.5 weeks) |
|
| Subject 3 (about 7 months) |
|
| Subject 3 (about 10 months) |
|
| Subject 4 (baseline) |
|
|
| Subject 4 (3.5 weeks) |
|
|
| Subject 4 (7 weeks) |
|
|
| Subject 4 (about 5 months) |
|
| Subject 4 (about 8 months) |
|
|
| Subject 6 (baseline) |
|
|
| Subject 6 (5.5 weeks) |
|
|
| Subject 6 (18.5 weeks) |
|
|
| Subject 6 (about 7 months) |
|
|
| Subject 6 (about 10 months) |
|
|
| Subject 7 (baseline) |
|
|
| Subject 7 (5.5 weeks) |
|
|
| Subject 7 (18.5 weeks) |
|
|
| Subject 7 (about 7 months) |
|
| Subject 7 (about 10 months) |
|
|
| Subject 8 (baseline) |
|
|
| Subject 8 (5.5 weeks) |
|
|
| Subject 8 (18.5 weeks) |
|
|
| Subject 8 (about 7 months) |
|
|
| Subject 8 (about 10 months) |
|
|
| Subject 9 (baseline) |
|
|
| Subject 9 (3.5 weeks) |
|
|
| Subject 9 (7 weeks) |
|
|
| Subject 9 (about 5 months) |
|
|
| Subject 9 (about 8 months) |
|
|
| Subject 10 (baseline) |
|
|
| Subject 10 (5.5 weeks) |
|
|
| Subject 10 (18.5 weeks) |
|
|
| Subject 10 (about 7 months) |
|
|
| Subject 10 (about 10 months) |
|
| Subject 12 (baseline) |
|
|
| Subject 12 (5.5 weeks) |
|
|
| Subject 12 (18.5 weeks) |
|
|
| Subject 12 (about 7 months) |
|
|
| Subject 12 (about 10 months) |
|
| Subject 2 (5.5 weeks) |
|
|
| Subject 2 (18.5 Weeks) |
|
|
| Subject 2 (about 7 months) |
|
|
| Subject 2 (about 10 months) |
|
|
| Subject 3 (baseline) |
|
|
| Subject 3 (5.5 weeks) |
|
|
| Subject 3 (18.5 weeks) |
|
| Subject 3 (about 7 months) |
|
| Subject 3 (about 10 months) |
|
| Subject 4 (baseline) |
|
|
| Subject 4 (3.5 weeks) |
|
|
| Subject 4 (7 weeks) |
|
|
| Subject 4 (about 5 months) |
|
| Subject 4 (about 8 months) |
|
|
| Subject 6 (baseline) |
|
|
| Subject 6 (5.5 weeks) |
|
|
| Subject 6 (18.5 weeks) |
|
|
| Subject 6 (about 7 months) |
|
|
| Subject 6 (about 10 months) |
|
|
| Subject 7 (baseline) |
|
|
| Subject 7 (5.5 weeks) |
|
|
| Subject 7 (18.5 weeks) |
|
|
| Subject 7 (about 7 months) |
|
| Subject 7 (about 10 months) |
|
|
| Subject 8 (baseline) |
|
|
| Subject 8 (5.5 weeks) |
|
|
| Subject 8 (18.5 weeks) |
|
|
| Subject 8 (about 7 months) |
|
|
| Subject 8 (about 10 months) |
|
|
| Subject 9 (baseline) |
|
|
| Subject 9 (3.5 weeks) |
|
|
| Subject 9 (7 weeks) |
|
|
| Subject 9 (about 5 months) |
|
|
| Subject 9 (about 8 months) |
|
|
| Subject 10 (baseline) |
|
|
| Subject 10 (5.5 weeks) |
|
|
| Subject 10 (18.5 weeks) |
|
|
| Subject 10 (about 7 months) |
|
|
| Subject 10 (about 10 months) |
|
| Subject 12 (baseline) |
|
|
| Subject 12 (5.5 weeks) |
|
|
| Subject 12 (18.5 weeks) |
|
|
| Subject 12 (about 7 months) |
|
|
| Subject 12 (about 10 months) |
|
| Subject 2 (iliac Crest, Cancellous, A) |
|
|
| Subject 2 (Iliac Crest, Endocortical, B) |
|
|
| Subject 2 (Iliac Crest, Endocortical, A) |
|
|
| Subject 2 (Iliac Crest, Intracortical, B) |
|
|
| Subject 2 (Iliac Crest, Intracortical, A) |
|
|
| Subject 2 (Iliac Crest, Periosteal, B) |
|
| Subject 2 (Iliac Crest, Periosteal, A) |
|
| Subject 2 (Sacrum, Cancellous, B) |
|
|
| Subject 2 (Sacrum, Cancellous, A) |
|
|
| Subject 2 (Sacrum, Endocortical, B) |
|
|
| Subject 2 (Sacrum, Endocortical, A) |
|
| Subject 2 (Sacrum, Intracortical, B) |
|
|
| Subject 2 (Sacrum, Intracortical, A) |
|
| Subject 2 (Sacrum, Periosteal, B) |
|
|
| Subject 2 (Sacrum, Periosteal, A) |
|
|
| Subject 3 (Iliac Crest, Cancellous, B) |
|
|
| Subject 3 (Iliac Crest, Cancellous, A) |
|
|
| Subject 3 (Iliac Crest, Endocortical, B) |
|
|
| Subject 3 (Iliac Crest, Endocortical, A) |
|
|
| Subject 3 (Iliac Crest, Intracortical, B) |
|
|
| Subject 3 (Iliac Crest, Intracortical, A) |
|
|
| Subject 3 (Iliac Crest, Periosteal, B) |
|
| Subject 3 (Iliac Crest, Periosteal, A) |
|
| Subject 3 (Sacrum, Cancellous, B) |
|
|
| Subject 3 (Sacrum, Cancellous, A) |
|
|
| Subject 3 (Sacrum, Endocortical, B) |
|
| Subject 3 (Sacrum, Endocortical, A) |
|
| Subject 3 (Sacrum, Intracortical, B) |
|
| Subject 3 (Sacrum, Intracortical, A) |
|
| Subject 3 (Sacrum, Periosteal, B) |
|
| Subject 3 (Sacrum, Periosteal, A) |
|
| Subject 6 (Iliac Crest, Cancellous, B) |
|
|
| Subject 6 (Iliac Crest, Cancellous, A) |
|
|
| Subject 6 (Iliac Crest, Endocortical, B) |
|
|
| Subject 6 (Iliac Crest, Endocortical, A) |
|
|
| Subject 6 (Iliac Crest, Intracortical, B) |
|
|
| Subject 6 (Iliac Crest, Intracortical, A) |
|
|
| Subject 6 (Iliac Crest, Periosteal, B) |
|
| Subject 6 (Iliac Crest, Periosteal, A) |
|
| Subject 6 (Sacrum, Cancellous, B) |
|
|
| Subject 6 (Sacrum, Cancellous, A) |
|
|
| Subject 6 (Sacrum, Endocortical, B) |
|
|
| Subject 6 (Sacrum, Endocortical, A) |
|
|
| Subject 6 (Sacrum, Intracortical, B) |
|
| Subject 6 (Sacrum, Intracortical, A) |
|
| Subject 6 (Sacrum, Periosteal, B) |
|
| Subject 6 (Sacrum, Periosteal, A) |
|
| Subject 7 (Iliac Crest, Cancellous, B) |
|
|
| Subject 7 (Iliac Crest, Cancellous, A) |
|
|
| Subject 7 (Iliac Crest, Endocortical, B) |
|
| Subject 7 (Iliac Crest, Endocortical, A) |
|
|
| Subject 7 (Iliac Crest, Intracortical, B) |
|
|
| Subject 7 (Iliac Crest, Intracortical, A) |
|
| Subject 7 (Iliac Crest, Periosteal, B) |
|
|
| Subject 7 (Iliac Crest, Periosteal, A) |
|
|
| Subject 7 (Sacrum, Cancellous, B) |
|
|
| Subject 7 (Sacrum, Cancellous, A) |
|
|
| Subject 7 (Sacrum, Endocortical, B) |
|
|
| Subject 7 (Sacrum, Endocortical, A) |
|
|
| Subject 7 (Sacrum, Intracortical, B) |
|
|
| Subject 7 (Sacrum, Intracortical, A) |
|
|
| Subject 7 (Sacrum, Periosteal, B) |
|
| Subject 7 (Sacrum, Periosteal, A) |
|
| Subject 8 (Iliac Crest, Cancellous, B) |
|
|
| Subject 8 (Iliac Crest, Cancellous, A) |
|
|
| Subject 8 (Iliac Crest, Endocortical, B) |
|
|
| Subject 8 (Iliac Crest, Endocortical, A) |
|
|
| Subject 8 (Iliac Crest, Intracortical, B) |
|
|
| Subject 8 (Iliac Crest, Intracortical, A) |
|
|
| Subject 8 (Iliac Crest, Periosteal, B) |
|
| Subject 8 (Iliac Crest, Periosteal, A) |
|
| Subject 8 (Sacrum, Cancellous, B) |
|
|
| Subject 8 (Sacrum, Cancellous, A) |
|
| Subject 8 (Sacrum, Endocortical, B) |
|
| Subject 8 (Sacrum, Endocortical, A) |
|
| Subject 8 (Sacrum, Intracortical, B) |
|
| Subject 8 (Sacrum, Intracortical, A) |
|
| Subject 8 (Sacrum, Periosteal, B) |
|
| Subject 8 (Sacrum, Periosteal, A) |
|
| Subject 10 (Iliac Crest, Cancellous, B) |
|
|
| Subject 10 (Iliac Crest, Cancellous, A) |
|
|
| Subject 10 (Iliac Crest, Endocortical, B) |
|
|
| Subject 10 (Iliac Crest, Endocortical, A) |
|
|
| Subject 10 (Iliac Crest, Intracortical, B) |
|
|
| Subject 10 (Iliac Crest, Intracortical, A) |
|
|
| Subject 10 (Iliac Crest, Periosteal, B) |
|
| Subject 10 (Iliac Crest, Periosteal, A) |
|
| Subject 10 (Sacrum, Cancellous, B) |
|
|
| Subject 10 (Sacrum, Cancellous, A) |
|
|
| Subject 10 (Sacrum, Endocortical, B) |
|
|
| Subject 10 (Sacrum, Endocortical, A) |
|
| Subject 10 (Sacrum, Intracortical, B) |
|
|
| Subject 10 (Sacrum, Intracortical, A) |
|
| Subject 10 (Sacrum, Periosteal, B) |
|
| Subject 10 (Sacrum, Periosteal, A) |
|
| Subject 12 (Iliac Crest, Cancellous, B) |
|
|
| Subject 12 (Iliac Crest, Cancellous, A) |
|
| Subject 12 (Iliac Crest, Endocortical, B) |
|
|
| Subject 12 (Iliac Crest, Endocortical, A) |
|
| Subject 12 (Iliac Crest, Intracortical, B) |
|
|
| Subject 12 (Iliac Crest, Intracortical, A) |
|
| Subject 12 (Iliac Crest, Periosteal, B) |
|
| Subject 12 (Iliac Crest, Periosteal, A) |
|
| Subject 12 (Sacrum, Cancellous, B) |
|
|
| Subject 12 (Sacrum, Cancellous, A) |
|
| Subject 12 (Sacrum, Endocortical, B) |
|
|
| Subject 12 (Sacrum, Endocortical, A) |
|
| Subject 12 (Sacrum, Intracortical, B) |
|
|
| Subject 12 (Sacrum, Intracortical, A) |
|
| Subject 12 (Sacrum, Periosteal, B) |
|
| Subject 12 (Sacrum, Periosteal, A) |
|
| Subject 2 (iliac Crest, Cancellous, A) |
|
|
| Subject 2 (Iliac Crest, Endocortical, B) |
|
|
| Subject 2 (Iliac Crest, Endocortical, A) |
|
|
| Subject 2 (Iliac Crest, Intracortical, B) |
|
|
| Subject 2 (Iliac Crest, Intracortical, A) |
|
|
| Subject 2 (Iliac Crest, Periosteal, B) |
|
|
| Subject 2 (Iliac Crest, Periosteal, A) |
|
|
| Subject 2 (Sacrum, Cancellous, B) |
|
|
| Subject 2 (Sacrum, Cancellous, A) |
|
|
| Subject 2 (Sacrum, Endocortical, B) |
|
|
| Subject 2 (Sacrum, Endocortical, A) |
|
| Subject 2 (Sacrum, Intracortical, B) |
|
|
| Subject 2 (Sacrum, Intracortical, A) |
|
|
| Subject 2 (Sacrum, Periosteal, B) |
|
|
| Subject 2 (Sacrum, Periosteal, A) |
|
|
| Subject 3 (Iliac Crest, Cancellous, B) |
|
|
| Subject 3 (Iliac Crest, Cancellous, A) |
|
|
| Subject 3 (Iliac Crest, Endocortical, B) |
|
|
| Subject 3 (Iliac Crest, Endocortical, A) |
|
|
| Subject 3 (Iliac Crest, Intracortical, B) |
|
|
| Subject 3 (Iliac Crest, Intracortical, A) |
|
|
| Subject 3 (Iliac Crest, Periosteal, B) |
|
|
| Subject 3 (Iliac Crest, Periosteal, A) |
|
|
| Subject 3 (Sacrum, Cancellous, B) |
|
|
| Subject 3 (Sacrum, Cancellous, A) |
|
|
| Subject 3 (Sacrum, Endocortical, B) |
|
| Subject 3 (Sacrum, Endocortical, A) |
|
| Subject 3 (Sacrum, Intracortical, B) |
|
| Subject 3 (Sacrum, Intracortical, A) |
|
| Subject 3 (Sacrum, Periosteal, B) |
|
| Subject 3 (Sacrum, Periosteal, A) |
|
| Subject 6 (Iliac Crest, Cancellous, B) |
|
|
| Subject 6 (Iliac Crest, Cancellous, A) |
|
|
| Subject 6 (Iliac Crest, Endocortical, B) |
|
|
| Subject 6 (Iliac Crest, Endocortical, A) |
|
|
| Subject 6 (Iliac Crest, Intracortical, B) |
|
|
| Subject 6 (Iliac Crest, Intracortical, A) |
|
|
| Subject 6 (Iliac Crest, Periosteal, B) |
|
|
| Subject 6 (Iliac Crest, Periosteal, A) |
|
|
| Subject 6 (Sacrum, Cancellous, B) |
|
|
| Subject 6 (Sacrum, Cancellous, A) |
|
|
| Subject 6 (Sacrum, Endocortical, B) |
|
|
| Subject 6 (Sacrum, Endocortical, A) |
|
|
| Subject 6 (Sacrum, Intracortical, B) |
|
|
| Subject 6 (Sacrum, Intracortical, A) |
|
|
| Subject 6 (Sacrum, Periosteal, B) |
|
|
| Subject 6 (Sacrum, Periosteal, A) |
|
|
| Subject 7 (Iliac Crest, Cancellous, B) |
|
|
| Subject 7 (Iliac Crest, Cancellous, A) |
|
|
| Subject 7 (Iliac Crest, Endocortical, B) |
|
| Subject 7 (Iliac Crest, Endocortical, A) |
|
|
| Subject 7 (Iliac Crest, Intracortical, B) |
|
|
| Subject 7 (Iliac Crest, Intracortical, A) |
|
| Subject 7 (Iliac Crest, Periosteal, B) |
|
|
| Subject 7 (Iliac Crest, Periosteal, A) |
|
|
| Subject 7 (Sacrum, Cancellous, B) |
|
|
| Subject 7 (Sacrum, Cancellous, A) |
|
|
| Subject 7 (Sacrum, Endocortical, B) |
|
|
| Subject 7 (Sacrum, Endocortical, A) |
|
|
| Subject 7 (Sacrum, Intracortical, B) |
|
|
| Subject 7 (Sacrum, Intracortical, A) |
|
|
| Subject 7 (Sacrum, Periosteal, B) |
|
|
| Subject 7 (Sacrum, Periosteal, A) |
|
|
| Subject 8 (Iliac Crest, Cancellous, B) |
|
|
| Subject 8 (Iliac Crest, Cancellous, A) |
|
|
| Subject 8 (Iliac Crest, Endocortical, B) |
|
|
| Subject 8 (Iliac Crest, Endocortical, A) |
|
|
| Subject 8 (Iliac Crest, Intracortical, B) |
|
|
| Subject 8 (Iliac Crest, Intracortical, A) |
|
|
| Subject 8 (Iliac Crest, Periosteal, B) |
|
|
| Subject 8 (Iliac Crest, Periosteal, A) |
|
|
| Subject 8 (Sacrum, Cancellous, B) |
|
|
| Subject 8 (Sacrum, Cancellous, A) |
|
| Subject 8 (Sacrum, Endocortical, B) |
|
| Subject 8 (Sacrum, Endocortical, A) |
|
| Subject 8 (Sacrum, Intracortical, B) |
|
| Subject 8 (Sacrum, Intracortical, A) |
|
| Subject 8 (Sacrum, Periosteal, B) |
|
| Subject 8 (Sacrum, Periosteal, A) |
|
| Subject 10 (Iliac Crest, Cancellous, B) |
|
|
| Subject 10 (Iliac Crest, Cancellous, A) |
|
|
| Subject 10 (Iliac Crest, Endocortical, B) |
|
|
| Subject 10 (Iliac Crest, Endocortical, A) |
|
|
| Subject 10 (Iliac Crest, Intracortical, B) |
|
|
| Subject 10 (Iliac Crest, Intracortical, A) |
|
|
| Subject 10 (Iliac Crest, Periosteal, B) |
|
|
| Subject 10 (Iliac Crest, Periosteal, A) |
|
|
| Subject 10 (Sacrum, Cancellous, B) |
|
|
| Subject 10 (Sacrum, Cancellous, A) |
|
|
| Subject 10 (Sacrum, Endocortical, B) |
|
|
| Subject 10 (Sacrum, Endocortical, A) |
|
| Subject 10 (Sacrum, Intracortical, B) |
|
|
| Subject 10 (Sacrum, Intracortical, A) |
|
| Subject 10 (Sacrum, Periosteal, B) |
|
|
| Subject 10 (Sacrum, Periosteal, A) |
|
|
| Subject 12 (Iliac Crest, Cancellous, B) |
|
|
| Subject 12 (Iliac Crest, Cancellous, A) |
|
| Subject 12 (Iliac Crest, Endocortical, B) |
|
|
| Subject 12 (Iliac Crest, Endocortical, A) |
|
| Subject 12 (Iliac Crest, Intracortical, B) |
|
|
| Subject 12 (Iliac Crest, Intracortical, A) |
|
| Subject 12 (Iliac Crest, Periosteal, B) |
|
| Subject 12 (Iliac Crest, Periosteal, A) |
|
| Subject 12 (Sacrum, Cancellous, B) |
|
|
| Subject 12 (Sacrum, Cancellous, A) |
|
| Subject 12 (Sacrum, Endocortical, B) |
|
|
| Subject 12 (Sacrum, Endocortical, A) |
|
| Subject 12 (Sacrum, Intracortical, B) |
|
|
| Subject 12 (Sacrum, Intracortical, A) |
|
| Subject 12 (Sacrum, Periosteal, B) |
|
|
| Subject 12 (Sacrum, Periosteal, A) |
|
| Subject 2 (Iliac Crest, Endocortical, A) |
|
|
| Subject 2 (Iliac Crest, Intracortical, A) |
|
|
| Subject 2 (Sacrum, Cancellous, A) |
|
|
| Subject 2 (Sacrum, Endocortical, A) |
|
| Subject 2 (Sacrum, Intracortical, A) |
|
| Subject 3 (Iliac Crest, Cancellous, A) |
|
|
| Subject 3 (Iliac Crest, Endocortical, A) |
|
|
| Subject 3 (Iliac Crest, Intracortical, A) |
|
|
| Subject 3 (Sacrum, Cancellous, A) |
|
|
| Subject 3 (Sacrum, Endocortical, A) |
|
| Subject 3 (Sacrum, Intracortical, A) |
|
| Subject 6 (Iliac Crest, Cancellous, A) |
|
|
| Subject 6 (Iliac Crest, Endocortical, A) |
|
|
| Subject 6 (Iliac Crest, Intracortical, A) |
|
|
| Subject 6 (Sacrum, Cancellous, A) |
|
|
| Subject 6 (Sacrum, Endocortical, A) |
|
|
| Subject 6 (Sacrum, Intracortical, A) |
|
| Subject 7 (Iliac Crest, Cancellous, A) |
|
|
| Subject 7 (Iliac Crest, Endocortical, A) |
|
|
| Subject 7 (Iliac Crest, Intracortical, A) |
|
| Subject 7 (Sacrum, Cancellous, A) |
|
|
| Subject 7 (Sacrum, Endocortical, A) |
|
|
| Subject 7 (Sacrum, Intracortical, A) |
|
|
| Subject 8 (Iliac Crest, Cancellous, A) |
|
|
| Subject 8 (Iliac Crest, Endocortical, A) |
|
|
| Subject 8 (Iliac Crest, Intracortical, A) |
|
|
| Subject 8 (Sacrum, Cancellous, A) |
|
| Subject 8 (Sacrum, Endocortical, A) |
|
| Subject 8 (Sacrum, Intracortical, A) |
|
| Subject 10 (Iliac Crest, Cancellous, A) |
|
|
| Subject 10 (Iliac Crest, Endocortical, A) |
|
|
| Subject 10 (Iliac Crest, Intracortical, A) |
|
|
| Subject 10 (Sacrum, Cancellous, A) |
|
|
| Subject 10 (Sacrum, Endocortical, A) |
|
| Subject 10 (Sacrum, Intracortical, A) |
|
| Subject 12 (Iliac Crest, Cancellous, A) |
|
| Subject 12 (Iliac Crest, Endocortical, A) |
|
| Subject 12 (Iliac Crest, Intracortical, A) |
|
| Subject 12 (Sacrum, Cancellous, A) |
|
| Subject 12 (Sacrum, Endocortical, A) |
|
| Subject 12 (Sacrum, Intracortical, A) |
|
| Subject 2 (week 6) |
|
|
| Subject 3 (week 5) |
|
|
| Subject 3 (week 6) |
|
|
| Subject 6 (week 5) |
|
|
| Subject 6 (week 6) |
|
|
| Subject 7 (week 5) |
|
|
| Subject 7 (week 6) |
|
|
| Subject 8 (week 5) |
|
|
| Subject 8 (week 6) |
|
|
| Subject 10 (week 5) |
|
| Subject 10 (week 6) |
|
| Subject 12 (week 5) |
|
| Subject 12 (week 6) |
|
| Subject 2 (week 6) |
|
|
| Subject 3 (week 5) |
|
|
| Subject 3 (week 6) |
|
|
| Subject 6 (week 5) |
|
|
| Subject 6 (week 6) |
|
|
| Subject 7 (week 5) |
|
|
| Subject 7 (week 6) |
|
|
| Subject 8 (week 5) |
|
|
| Subject 8 (week 6) |
|
|
| Subject 10 (week 5) |
|
| Subject 10 (week 6) |
|
| Subject 12 (week 5) |
|
| Subject 12 (week 6) |
|
| Subject 2 (week 6) |
|
|
| Subject 3 (week 5) |
|
|
| Subject 3 (week 6) |
|
|
| Subject 6 (week 5) |
|
|
| Subject 6 (week 6) |
|
|
| Subject 7 (week 5) |
|
|
| Subject 7 (week 6) |
|
|
| Subject 8 (week 5) |
|
|
| Subject 8 (week 6) |
|
|
| Subject 10 (week 5) |
|
| Subject 10 (week 6) |
|
| Subject 12 (week 5) |
|
| Subject 12 (week 6) |
|
| Subject 2 (week 6) |
|
|
| Subject 3 (week 5) |
|
|
| Subject 3 (week 6) |
|
|
| Subject 6 (week 5) |
|
|
| Subject 6 (week 6) |
|
|
| Subject 7 (week 5) |
|
|
| Subject 7 (week 6) |
|
|
| Subject 8 (week 5) |
|
|
| Subject 8 (week 6) |
|
|
| Subject 10 (week 5) |
|
| Subject 10 (week 6) |
|
| Subject 12 (week 5) |
|
| Subject 12 (week 6) |
|